EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of HER2 and Nectin-4 Expression in Primary Vaginal Cancers

Gilbert Georg Klamminger iD, Hanna Wattendorff, Felix Hässlin, Christoph Eckert, Silke Mitschke, Stefanie Zimmer, Meletios P Nigdelis iD, Roxana Schwab iD, Walburgis Brenner iD, Annette Hasenburg iD, Yaman Degirmenci iD

International Journal of Molecular Sciences · 05.08.2026 · 27 (15) · 7018

DOI: 10.3390/ijms27157018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 05.08.2026. Verfasst von Gilbert Georg Klamminger und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Cell Adhesion Molecules, Vaginal Neoplasms, Nectins. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study assessed the prevalence and clinical relevance of p16INK4a, p53, HER2, and Nectin-4 protein expression in primary vaginal cancer (PVC), with HER2 and Nectin-4 representing potentially druggable targets. A total of 34 patients with PVC from the University Medical Center Mainz biobank were included. Immunohistochemistry was used to evaluate the expression of p16, p53, HER2, and Nectin-4: p16, p53, and HER2 staining results were dichotomized (positive vs. negative; mutant vs. wildtype staining pattern), whereas Nectin-4 expression was assessed using an immunoreactive score (IRS) based on staining intensity and the proportion of positive tumor cells. Univariate analyses were performed to identify intergroup differences, and survival analyses were conducted using the log-rank test. Negative p16 expression was significantly associated with adenocarcinomatous histology (p = 0.0211), but neither p16 nor p53 status showed prognostic relevance. HER2 positivity was detected in 14.7% of tumors and was significantly associated with adenocarcinoma (p = 0.0001), p16 negativity (p = 0.0035), and younger age (p = 0.0483). Based on IRS, strong total Nectin-4 expression was observed in 20.59% and moderate membranous Nectin-4 expression in 17.65% of cases. No significant associations were found between HER2 or Nectin-4 expression and clinical outcomes; however, a limited statistical power of the survival analysis due to the low number of events (n = 10 deaths) should be considered. This analysis demonstrates a notable prevalence of HER2 and Nectin-4 expression in PVC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesCell Adhesion MoleculesVaginal NeoplasmsNectinsHumansFemaleMiddle AgedAgedBiomarkers, TumorPrognosisImmunohistochemistryTumor Suppressor Protein p53Aged, 80 and overAdultCyclin-Dependent Kinase Inhibitor p16

Stichwörter der Autor:innen

HER2Nectin-4druggable targetsprimary vaginal cancertumor-agnostic therapy

Substanzen

NECTIN4 protein, humanErb-b2 Receptor Tyrosine KinasesCell Adhesion MoleculesERBB2 protein, humanBiomarkers, TumorTumor Suppressor Protein p53NectinsCyclin-Dependent Kinase Inhibitor p16

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
  • Institute of Pathology, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
  • TRON-Translational Oncology Mainz gGmbH, 55131 Mainz, Germany.
  • Tissue Bank of the University Medical Center Mainz, 55131 Mainz, Germany.
  • Department of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Medical Center (UKS), 66424 Homburg, Germany.

ORCID-Profile: Gilbert Georg Klamminger, Meletios P Nigdelis, Roxana Schwab, Walburgis Brenner, Annette Hasenburg, Yaman Degirmenci

Zitieren

APA

Klamminger, G. G., Wattendorff, H., Hässlin, F., Eckert, C., Mitschke, S., Zimmer, S., Nigdelis, M. P., Schwab, R., Brenner, W., Hasenburg, A., & Degirmenci, Y. (2026). Evaluation of HER2 and Nectin-4 Expression in Primary Vaginal Cancers. International Journal of Molecular Sciences, 27(15), 7018. https://doi.org/10.3390/ijms27157018

Vancouver

Klamminger GG, Wattendorff H, Hässlin F, Eckert C, Mitschke S, Zimmer S, et al. Evaluation of HER2 and Nectin-4 Expression in Primary Vaginal Cancers. International Journal of Molecular Sciences. 2026;27(15):7018. doi:10.3390/ijms27157018

BibTeX
@article{Klamminger2026,
  author = {Klamminger, Gilbert Georg and Wattendorff, Hanna and Hässlin, Felix and Eckert, Christoph and Mitschke, Silke and Zimmer, Stefanie and Nigdelis, Meletios P and Schwab, Roxana and Brenner, Walburgis and Hasenburg, Annette and Degirmenci, Yaman},
  title = {Evaluation of HER2 and Nectin-4 Expression in Primary Vaginal Cancers},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {15},
  pages = {7018},
  doi = {10.3390/ijms27157018}
}
Kostenlos starten →